Filtered By:
Specialty: Epidemiology
Drug: Temodar
This page shows you your search results in order of date.
Order by Relevance | Date
Total 32 results found since Jan 2013.
Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma
CONCLUSION: Apparent survival benefit of extended adjuvant TMZ in newly diagnosed GBM is largely driven by nonrandomized comparative studies with high inherent potential for multiple biases.PMID:37638346 | PMC:PMC10457033 | DOI:10.1093/noajnl/vdad086
Source: Adv Data - August 28, 2023 Category: Epidemiology Authors: Tejpal Gupta Jeevi Mona Priyadharshni Selvarajan Sadhana Kannan Nandini Menon Archya Dasgupta Abhishek Chatterjee Source Type: research
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression
CONCLUSIONS: High NLR is associated with worse outcomes in newly diagnosed and recurrent glioblastoma. Appropriate eligibility criteria and accounting and reporting of blood-based biomarkers are important in the design and interpretation of newly diagnosed and recurrent glioblastoma trials.PMID:37554224 | PMC:PMC10406420 | DOI:10.1093/noajnl/vdad083
Source: Adv Data - August 9, 2023 Category: Epidemiology Authors: Davy Deng Lubna Hammoudeh Gilbert Youssef Yu-Hui Chen Kee-Young Shin Mary Jane Lim-Fat Jose Ricardo McFaline-Figueroa Ugonma N Chukwueke Shyam Tanguturi David A Reardon Eudocia Q Lee Lakshmi Nayak Wenya Linda Bi Omar Arnaout Keith L Ligon Patrick Y Wen Ri Source Type: research
Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas
CONCLUSIONS: Combination of PAC-1 and TMZ was well tolerated up to 625 mg orally daily and TMZ orally 150 mg/m2/5 days per 28-day cycle. The maximum tolerated dose was not reached. Further dose escalation of PAC-1 in combination with TMZ is advised before conducting a formal prospective efficacy study in this patient population.PMID:37554223 | PMC:PMC10406430 | DOI:10.1093/noajnl/vdad087
Source: Adv Data - August 9, 2023 Category: Epidemiology Authors: Matthias Holdhoff M Kelly Nicholas Richard A Peterson Stefania Maraka Li C Liu James H Fischer Jeffrey S Wefel Timothy M Fan Tracy Vannorsdall Meredith Russell Michaella Iacoboni Theodore M Tarasow Paul J Hergenrother Arkadiusz Z Dudek Oana C Danciu Source Type: research
Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production
We present a previously unidentified understanding of chemoresistance through critical RRM2-mediated nucleotide production.PMID:37196077 | DOI:10.1126/sciadv.ade7236
Source: Adv Data - May 17, 2023 Category: Epidemiology Authors: Ella N Perrault Jack M Shireman Eunus S Ali Peiyu Lin Isabelle Preddy Cheol Park Shreya Budhiraja Shivani Baisiwala Karan Dixit C David James Dieter H Heiland Issam Ben-Sahra Sebastian Pott Anindita Basu Jason Miska Atique U Ahmed Source Type: research
A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors
CONCLUSION: The latest available data on the epidemiology, diagnosis, molecular changes, and treatment of G3 GEP NET are described. Yet, the level of evidence for treatment recommendations is low, as most studies are retrospective. A treatment algorithm for G3 GEP NET is proposed.PMID:36950274 | PMC:PMC10026121 | DOI:10.1177/17588359231156218
Source: Adv Data - March 23, 2023 Category: Epidemiology Authors: Mauro D Donadio Ângelo B Brito Rachel P Riechelmann Source Type: research
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
CONCLUSIONS: Trotabresib combined with TMZ in the adjuvant setting and with TMZ+RT in the concomitant setting was safe and well tolerated in patients with ndGBM, with encouraging treatment durations. Trotabresib 30 mg was established as the RP2D in both settings.PMID:36382109 | PMC:PMC9653173 | DOI:10.1093/noajnl/vdac146
Source: Adv Data - November 16, 2022 Category: Epidemiology Authors: Maria Vieito Matteo Simonelli Filip de Vos Victor Moreno Marjolein Geurts Elena Lorenzi Marina Macchini Martin J van den Bent Gianluca Del Conte Maja de Jonge Maria Cruz Mart ín-Soberón Barbara Amoroso Tania Sanchez-Perez Marlene Zuraek Bishoy Hanna Ida Source Type: research
On optimal temozolomide scheduling for slowly growing glioblastomas
CONCLUSIONS: In-silico simulations, in-vitro and in-vivo studies show that TMZ administration schedules with increased time between doses may reduce toxicity, delay the appearance of resistances and lead to survival benefits mediated by changes in the tumor phenotype in slowly-growing GBMs.PMID:36325374 | PMC:PMC9616068 | DOI:10.1093/noajnl/vdac155
Source: Adv Data - November 3, 2022 Category: Epidemiology Authors: Berta Segura-Collar Juan Jim énez-Sánchez Ricardo Gargini Miodrag Dragoj Juan M Sep úlveda-Sánchez Milica Pe šić Mar ía A Ramírez Luis E Ayala-Hern ández Pilar S ánchez-Gómez V íctor M Pérez-García Source Type: research
Germline polymorphisms in < em > MGMT < /em > associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825
CONCLUSIONS: Myelotoxicity during concurrent chemoradiation with temozolomide is an uncommon but serious event, often leading to treatment cessation. Successful prediction of toxicity may lead to more cost-effective individualized monitoring of at-risk subjects. The addition of genetic factors greatly enhanced our ability to predict toxicity among a group of similarly treated glioblastoma patients.PMID:36299794 | PMC:PMC9587696 | DOI:10.1093/noajnl/vdac152
Source: Adv Data - October 27, 2022 Category: Epidemiology Authors: Michael E Scheurer Renke Zhou Mark R Gilbert Melissa L Bondy Erik P Sulman Ying Yuan Yanhong Liu Elizabeth Vera Merideth M Wendland Emad F Youssef Volker W Stieber Ritsuko R Komaki John C Flickinger Lawrence C Kenyon H Ian Robins Grant K Hunter Ian R Croc Source Type: research
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed < em > MGMT < /em > promoter methylated < em > IDH < /em > wildtype glioblastoma
CONCLUSIONS: The results from this multicentric trial indicate that-under real-life conditions-toxicity and survival estimates are comparable to the CeTeG/NOA-09 trial. TTFields therapy for at least eight weeks in combination with this regimen was independently associated with prolonged survival.PMID:36284931 | PMC:PMC9583686 | DOI:10.1093/noajnl/vdac137
Source: Adv Data - October 26, 2022 Category: Epidemiology Authors: Lazaros Lazaridis Elisabeth Bumes Dorothee C äcilia Spille Tim Schulz Sina Heider Sarina Agkatsev Teresa Schmidt Tobias Blau Christoph Oster Jonas Feldheim Walter Stummer Almuth Friederike Kessler Clemens Seidel Oliver Grauer Peter Hau Ulrich Sure Kathy Source Type: research
